Compare · ABBV vs PROC
ABBV vs PROC
Side-by-side comparison of AbbVie Inc. (ABBV) and Procaps Group S.A. (PROC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and PROC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $397.12B, about 377.3x PROC ($1.05B).
- ABBV has hit the wire 11 times in the past 4 weeks while PROC has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 0 for PROC).
- Company
- AbbVie Inc.
- Procaps Group S.A.
- Price
- $224.59-0.14%
- $1.16-27.50%
- Market cap
- $397.12B
- $1.05B
- 1M return
- +8.04%
- -
- 1Y return
- +16.77%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 0
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Procaps Group S.A.
Procaps Group, S.A. develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and clinical solutions. It operates in 13 countries in Latin America. The company was founded in 1977 and is based in Luxembourg City, Luxembourg
Latest ABBV
- Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
Latest PROC
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Receives Additional Delinquency Letter
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
- Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.